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ABSTRACT
Background: Prostate cancer is the second most incident of the male population in Brazil. The aim of 
this study is to analyze the frequency of risk factors associated to the evolution of the prostate cancer 
and the impact of conducting examinations in the age range (55-69 years old), in assisting health 
professionals to manage and prevent the disease. Methods: A case-control study was performed on 
patients from 2011 to 2016 in Criciúma – SC, Brazil. The sample was divided into two groups, one 
with biopsy for prostate adenocarcinoma (case; n = 124) and the other with a negative biopsy (con-
trol; n = 251). The following variables were compared between the two groups: age, family history 
of prostate cancer, prostate specific antigen, and altered digital rectal examination. Results: In the 
case group, ranging between 55-69 years old, there was a significant higher of altered digital rec-
tal examination (p < 0.001, odds ratio 15.5 and positive predictive value 91.3%), prostate-specific 
antigen ≥ 4 ng/mL (p < 0.001, odds ratio 7.02 and positive predictive value 56.2%) and when both 
exams were altered (p < 0.001, odds ratio was 19.63 and the positive predictive value was 90.5%). 
Conclusion: This findings show that, mainly between 55-69 years old, there is a significant correla-
tion between positive biopsy, altered digital rectal examination, and PSA ≥ 4 ng/mL.
Keywords: Prostate-Specific Antigen. Digital Rectal Examination. Risk Factors. Prostatic Neoplasms. 
Prostate. 
RESUMO
Objetivo: O câncer de próstata é o segundo mais incidente na população masculina no Brasil. 
O objetivo do estudo é analisar a frequência dos fatores de risco associados ao desenvolvimento do 
câncer de próstata e o impacto da realização de exames na faixa etária de rastreamento (55-69 anos), 
auxiliando os profissionais de saúde no manejo e prevenção da doença. Método: Foi realizado um 
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estudo caso-controle no período de 2011 a 2016 em Criciúma – SC, Brasil. A amostra foi dividida em 
dois grupos, um com biópsia de adenocarcinoma de próstata (casos; n = 124) e outro com biópsia 
negativa (controles; n = 251). Entre ambos os grupos, foram comparadas as variáveis: idade, histó-
ria familiar de câncer de próstata, antígeno prostático específico e toque retal alterado. Resultados: 
No grupo dos casos, na faixa etária entre 55-69 anos, ocorreu maior significância de toque retal alterado 
(p < 0,001; odds ratio 15.5 e valor preditivo positivo 91,3%), antígeno prostático específico ≥ 4 ng/mL 
(p < 0,001; odds ratio 7.02 e valor preditivo positivo 56,2%) e quando os dois exames estavam alterados 
(p < 0,001; odds ratio 19.63 e valor preditivo positivo 90,5%). Conclusão: Há evidências, principal-
mente entre 55-69 anos, de maior correlação de biópsia positiva, toque retal alterado e PSA ≥ 4 ng/mL.
Palavras-chave: Antígeno Prostático Específico. Exame Retal Digital. Fatores de Risco. Neoplasias 
da Próstata. Próstata.
INTRODUCTION
Prostate cancer is the second most incident 
form of cancer of the male population in Brazil, 
behind only non-melanoma skin cancer.1 In 2017, 
prostate, lung and bronchial and colorectal rep-
resented 42% of all cases of cancers in men, and 
it is responsible for 1 in 5 new diagnoses.2 It has 
an annual incidence rate of 233,000 cases in the 
United States and 382,000 cases in Europe.3 In 
Brazil, there were estimated 68,000 new cases 
in 2018, representing a problem of public health.1
The risk factor is something that alters the 
possibility of an individual acquiring a disease; 
however, having a risk factor does not necessarily 
indicate that the disease will actually evolve. 
While some patients have more than one risk 
factor and do not develop the disease, others 
may have few or none of the known factors and 
develop the disease.4
The risk factors for prostate cancer are not 
totally known, but three are well-established: 
advanced age, ethnicity, and heredity, that this, 
unmodifiable risk factors.5 It is an age-related ne-
oplasm in which 75% of cases occur in men over 
65 years. The studies show a direct association 
between the increased risk of prostate cancer and 
family members with the same disease.6 Prostate 
adenocarcinoma is one of the most hereditary ne-
oplasms with a hereditary factor, with an estimat-
ed 42% of the risk attributed to genetic factors.7 
The influence of modifiable factors (smoking, al-
coholism, diet, obesity, vasectomy, and previous 
history of sexually transmitted disease) is uncer-
tain.8 Knowledge about the factors related to the 
development of prostate cancer is fundamental, 
since, in addition to helping in better clinical man-
agement, it is also a means for the elaboration of 
preventive measures in relation to the onset and 
development of the disease. 
The prostate cancer mortality rate de-
creased by about 50% due to improvements in 
detection and early treatment.2 However, screen-
ing through prostate-specific antigen (PSA) has 
also attributed to excessive diagnosis and treat-
ment, and the need to perform the test was wide-
ly debated.7 In some men, the disease would nev-
er become symptomatic during life and treatment 
would not provide benefits, called overdiagnosis,9 
explaining in autopsy studies the high prevalence 
of undetected prostate cancer.10
The particular contribution of the current 
study is to analyze the frequency of risk factors (age 
and family history) associated with prostate cancer 
development and the impact of PSA and digital rec-
tal examination (DRE) in the age group of screening 
(55-69 years old), assisting health professionals in 
the management and prevention of the disease.
METHODS
It was a case-control study in which pa-
tients’ charts of prostate biopsies were analyz-
ed, and they were attended in private clinics of 
Criciúma (SC) between 2011 to 2016. The sam-
ple consisted of 375 patients’ charts that were 
divided into two groups, one group with pos-
itive biopsy for adenocarcinoma of the prostate 
(case: n = 124) and the other with negative bi-
opsy (control; n = 251). Between the two groups, 
the following variables were compared: age, fam-
ily history (FH) of prostate cancer, PSA, and al-
tered DRE. 
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The inclusion criteria were: patients who un-
derwent prostate biopsy, family history of prostate 
cancer, altered DRE, and PSA. The exclusion crite-
ria were: incomplete medical records, other his-
tological types of prostate cancer other than ade-
nocarcinoma. Controls were selected among those 
who performed the biopsy but found a negative 
result for malignancy.
The study was approved by the Ethics and 
Research Committee of Universidade do Extremo 
Sul Catarinense (UNESC) under the number 
1.870.176/2016 and CAAE 62768416.9.0000.0119, 
and it was initiated after the signing of the Confi-
dentiality Agreement and approval of the study by 
the aforementioned committee.
The data collected was analyzed using the 
IBM Statistical Package for Social Sciences (SPSS) 
software version 22.0. Qualitative variables were 
expressed by means of frequency and percentage.
The statistical tests were performed with a 
significance level α = 0.05 and, thus, with a confi-
dence interval (CI) of 95%.
The investigation of the existence of an as-
sociation between the qualitative variables was 
performed through the Chi-square test and the 
Fisher’s exact test, followed by residue analysis 
when statistical significance was observed.
After the univariate and bivariate analysis, 
a logistic regression analysis was performed using 
the odds ratio (OR) as a measure of the strength 
of association between the variables.
RESULTS
This study analyzed only the medical records 
of patients who underwent prostate biopsy, selecting 
the sample from the inclusion and exclusion criteria, 
already mentioned, totaling 375 medical records. The 
groups (positive biopsy, n = 124) and control (neg-
ative biopsy, n = 251) were divided into patients 
younger than 54 years old, aged 55-69 and older 
than 70 years old, resulting in 14 patients with adeno-
carcinoma of the prostate: 14 (11.3%), 79 (63.7%), 
and 31 (25%) cases, respectively. (Table 1).
Table 1
General characteristics of the samples searched
Prostate Cancer Confidence interval 95%
Yes No p value odds ratio Lower Upper
n = 124 n = 251
Age (years)
≤ 54 14 (11.3) 25 (9.0)
55-69 79 (63.7) 126 (50.1)
≥ 70 31 (25.0) 100 (39.9) 0.017 2.02 1.24 3.31
Family History
Yes 15 (12.1) 13 (5.2) 0.017 2.52 1.16 5.48
No 109 (87.9) 238 (94.8)
Altered digital rectal examination
Yes 32 (25.8) 12 (4.8) <0.001 2.82 1.93 4.13
No 92 (74.2) 23 (95.2)
Fonte: Ives YK, et al. Prostate cancer profiles and associated factors in Criciúma – Santa Catarina, Brazil; 2019.
When comparing the family history, there 
were found 15 (12.1%) patients in the case group 
concerning the other with negative biopsy, be-
ing statistically significant (p = 0.017; OR 2.52; 
95% CI 1.16-5.48).
In the group with prostate cancer, the presence 
of altered DRE (nodularity, induration, and asym-
metry) totaled 32 (25.8%) cases and represented 
statistical significance (p < 0.001). It can be no-
ticed that the presence of family history (p = 0.017) 
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and altered DRE (p < 0.001) were initially signifi-
cant for the presence of prostate cancer. However, 
by including both factors in a logistic regression 
equation, only altered DRE remained significant 
(p < 0.001; OR 2.82; IC 95% 1.93-4.13).
The case and control groups were divid-
ed into PSA < 4 and ≥ 4 ng/mL and multivar-
iate analysis was performed at ages between 
55-69 and > 70 years old and altered DRE was 
used to determine whether there was a relation-
ship between the factors jointly and not only in a 
way independent. In patients aged 55-69 years 
old, it was found OR 7.02 if PSA ≥ 4 ng/mL with 
p < 0.001 (95% CI 3.29-14.98), OR 15.5 if altered 
DRE with p < 0.001 (95% CI 3.33-72.57) and, if 
both factors are present, there is OR 19.63 of pos-
itive biopsy with p < 0.001 (95% CI 4.43-87.05). 
In the group > 70 years old, both PSA ≥ 4 ng/mL 
and altered DRE were not significant (p = 0.063 
and 0.095, respectively) and also associated 
(p = 0.053).
DISCUSSION
The National Cancer Institute stipulates age 
as the leading risk factor for prostate cancer, as 
approximately 75% of cases occur after the age 
of 65.6 Age is widely discussed in the literature 
as a parameter for screening and risks and ben-
efits. Based on clinical trials, the American Uro-
logical Association (AUA) and the Canadian Task 
Force on Preventive Health Care consider that 
patients aged 55-69 years old are candidates for 
screening and are not recommended for those 
over 70.11 Our study demonstrated that the high-
est percentage of positive biopsies were in the in-
dication range of screening (63.7%) with OR 2.02 
(95% CI 1.24-3.31) and, in the not recommended 
range, the results of the DRE and PSA ≥ 4 ng/mL 
were not statistically significant (p = 0.063 and 
p = 0.095, respectively). The United States Pre-
ventive Services Task Force (USPSTF) states that 
screening between 55-69 years old should be in-
dividualized based on professional judgment and 
patient decisions, assessing the consequences and 
benefits, since for every 1,000 men selected there 
would be prevention of 1-2 deaths from prostate 
cancer and 3 cases of prostate cancer, but 1 in 5 
cases develop incontinence and 2 in 3 erectile dys-
function after radical prostatectomy and more than 
half acquire sexual impotence after chemotherapy, 
exposing that net benefit caused by the tracing is 
small (level of evidence C).12 In some men, the 
disease would never become symptomatic during 
life and treatment would not provide them with 
benefits, being called overdiagnosis. Mainly in 
> 70 years old, this phenomenon occurs in 20-50% 
of those diagnosed by screening.11 In the present 
study, > 70 years old, 23.7% of positive biopsies 
occurred. The Ministry of Health also does not 
indicate the population screening, due to lack of 
evidence that treatment in the early stages has 
an effectiveness that exceeds the risks of adverse 
effects, and should also be individualized cases.13
Current literature considers family histo-
ry as one of the few established risk factors for 
prostate cancer and is used as a parameter for 
disease screening.5 In a randomized study that 
evaluated 10,311 men aged 55-70 years old, it was 
shown a greater risk OR = 1.61 (95% CI 1.20-2.16) 
compared to the non-FH group.3 Likewise, in an-
other study with 23,702 patients, the presence 
of FH represented a higher risk of adenocarcino-
ma relative risk (RR) 1.31 (p < 0.001).14 The re-
sults of our study showed that 12.1% of the cases 
were associated with a higher number of patients 
with adenocarcinoma (p = 0.017) with OR = 2.52 
(95% CI 1.16 - 5.48) compared to the control 
group, but it lost significance after being includ-
ed in a logistic regression analysis, since patients 
with FH sought medical care due to the variable 
itself, causing a confounding event in the sam-
ple. Although family history is a method used to 
determine the risk of developing the disease,15 
it is present in <10% of men.16 In this re-
spect, it is worth noting the reason for the var-
iable being incorporated in risk calculators cur-
rently available.5 Besides, the American Cancer 
Society (ACS), the AUA, and the National Com-
prehensive Network (NCCN) recommend early 
and selective screening in men with a positive 
family history of prostate cancer.17
The most common tests used for the diag-
nosis of prostate cancer are: DRE, PSA, and biopsy 
guided by transrectal ultrasonography.18 PSA is a 
protein secreted by acinar cells of the prostate. PSA 
serum levels in clinical use since 1986 are the tumor 
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marker, although the usefulness of screening for 
prostate cancer is controversial and widely debated 
in the literature, is useful for diagnosis.19 According 
to the NCCN, there is no PSA level below which the 
risk of prostate cancer can be excluded. The disease 
is generally suspected on altered DRE examination, 
whether or not accompanied by elevated PSA lev-
el. The definitive diagnosis depends on the histo-
pathological result.20 In a cohort study with 4,932 
men, it was found that patients between the ages 
of 57-61 in a multivariate analysis, PSA ≥ 3 ng/dL 
(HR 1.13 and 95% CI 1.12-1.14) and FH positive 
(HR 1.6 and 95% CI 1.24-2.14) were independent 
predictors for prostate cancer (all with p < 0.001).3 
In our study, patients between 55-69 years old, 
in a multivariate analysis, either independently, 
PSA ≥ 4 ng/dL (OR 8.51 and 95% CI 4.11-17.64) 
and FH positive (OR 2.75 and 95% CI 1.02-7.43), 
as associated, were significant (p = 0.0001 and 
p = 0.034, respectively). We did not find in the lit-
erature a study that also analyzed, in the range of 
age for tracing, both factors.
DRE can detect palpable abnormalities (nodules, 
asymmetry, and induration) in the posterior and lat-
eral regions of the prostate gland where most cancers 
arise, but in other areas that may also be affected by 
the disease, are not reachable by the exam.21 In a study 
of 6,630 patients aged 50-96 years old, PSA ≥ 4 ng/dL 
(OR = 8.36, 95% CI 5.38-12.98, and p = 0.0001) 
showed a positive predictive value (PPV) of 32% 
and altered DRE (OR = 2.82, IC 95% 1.93-4.13 and 
p = 0.0001) PPV of 21%. When both exams were 
altered, the PPV was 49%.22 In the present study, 
PSA ≥ 4 ng/dL (OR = 7.02, 95% CI 3.29-14.98 
and < 0.0001) presented a PPV of 56.2%, the al-
tered DRE (OR = 15.5, CI 95% 3.33-72.57 
and p < 0.0001) 91.3% and, when associated 
(OR = 19.63, 95% CI 4.43-87.05 and < 0.0001), 
90.5%. In > 70 years old, the PPV was respectively 
30.3%, 46.2%, and 50%. In a study of 1,472 pa-
tients, it was demonstrated that no PSA level was 
associated with a 100% PPV and a negative biopsy 
could occur at almost any level of PSA.23
CONCLUSION
There is evidence that the age group be-
tween 55-69 years old shows a higher correlation 
with positive biopsy, altered DRE, and PSA ≥ 4 ng/
mL, corroborating with literature the importance of 
evaluation in this profile of patients. In the popula-
tion above the age of 70, it is necessary to consid-
er the cost-benefit of the treatment of the disease, 
since, in addition to the effects that the treatment 
can trigger, many will be asymptomatic.
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